Helen Sabzevari
CIK 1724195 · President and CEO · last filed 2026-06-01
Helen Sabzevari is a President and CEO who has filed 52 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider sold $519.9K of PGEN on Jun 1, 2026. Across all open-market trades the lifetime net is −$4.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$16.77M
3
52
-$4.85M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | President and CEO | 3,768,872 | $4.45 | $16.77M | -$4.49M | 35 | 2026-06-01 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | — | $2.65 | — | $0 | 3 | 2023-06-13 |
| PRECIGEN, INC. (XON) Delisted | President and CEO | 104,734 | — | — | -$366.3K | 13 | 2020-01-07 |
Recent Filings
52 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-01 | PGEN | Sell (S) | −119,250 | -$519.9K | EDGAR |
| 2026-05-27 | PGEN | Exer (M) | +250,000 | $0 | EDGAR |
| 2026-04-22 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2026-03-20 | PGEN | Mixed | +321,100 | $0 | EDGAR |
| 2025-09-16 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2025-06-27 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2025-05-27 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2025-05-16 | PGEN | Mixed | +557,913 | -$755.8K | EDGAR |
| 2025-04-18 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2025-02-03 | PGEN | Mixed | +538,033 | -$373.1K | EDGAR |